Breast cancer survival rates 'not affected by faulty BRCA gene mutation'

Breast cancer survival rates 'not affected by faulty BRCA gene mutation'

Breast cancer survival rates 'not affected by faulty BRCA gene mutation'

The FDA has approved olaparib (Lynparza, AstraZeneca/Merck) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.

Young breast cancer patients with faulty BRCA genes have the same survival chances as those without, a study has found.

PARP inhibitors have already "been used to treat advanced, BRCA-mutated ovarian cancer and have now shown efficacy in treating certain types of BRCA-mutated breast cancer", Dr. Richard Pazdur, who directs the FDA's Oncology Center of Excellence, explained in an agency news release. "Decisions about timing of additional surgery to reduce future cancer risks should take into account patient prognosis after their first cancer, and their personal preferences". In 2011, Domchek also led the organization of the worldwide team of physician scientists known as BRCA-TAC, which led a charge to advance clinical testing of olaparib in cancer patients with known inherited mutations in BRCA1 and BRCA2. AstraZeneca and Merck are working together to deliver Lynparza as quickly as possible to more patients across multiple settings, including breast, ovarian, prostate, and pancreatic cancers. Recruitment stopped in 2008, and long-term follow-up is continuing.

Some 89 per cent underwent chemotherapy.

About a third of those included in the study with the BRCA mutation had a double mastectomy to remove both breasts after being diagnosed with cancer.

However, the researchers noted the results might not translate to older women with a BRCA mutation, as they were not involved in the study and more research would be needed in this area. The secondary outcome was distant disease-free survival, defined as time from initial diagnosis to first distant disease.

Find out more about BRCA1 and BRCA2 at the U.S. Few studies have looked at whether these genes are linked with lower survival in young breast cancer patients, which this research aimed to address. About 5 percent to 10 percent of patients with breast cancer have a BRCA mutation.

The median follow-up was 8.2 years.

After the women's medical records were tracked for up to ten years, researchers found that 651 of 678 total deaths were due to breast cancer. After five years, survival rates were 83.8 percent and 85 percent, respectively. Affects one in 800 women, up to 70 per cent increased risk.

MCM8 - Also associated with early menopause.

BRCA1 - Led Angelina Jolie to have a double mastectomy because of her risk of breast cancer. BRCA-related breast cancer often strikes younger people and is harder to treat than other breast cancers.

Related news